Skye Bioscience

Skye Bioscience announced the opening of Cohort 2 in the CBeyond Part C Expansion Study after favorable safety data from the first four participants treated in Cohort 1. The progression into Cohort 2 marks an important step forward as the study continues evaluating nimacimab as a potential treatment for obesity and metabolic health. The company remains on track to report topline data from the expansion study in Q4 2026. Read more: ir.skyebioscience.com/news-releases/… #Biotech #Obesity #ClinicalDevelopment

Skye Bioscience reported first quarter 2026 financial results and business updates as the company advances nimacimab in obesity. During the quarter, Skye initiated Part C of the CBeyond™ Expansion Study and advanced activities supporting a Phase 2b-ready program. This included ENHANZE compatibility work for high-volume subcutaneous delivery and engagement with Lilly Catalyze360-ExploR&D on target product profile and trial design strategy. The company remains on track to report topline CBeyond Expansion Study data in Q4 2026. Read the full update: ir.skyebioscience.com/news-releases/… #biotech #obesity #clinicaldevelopment

In 2026, Skye is focused on defining the optimal dose and development path for nimacimab as a differentiated add-on to GLP-1 therapies like semaglutide. Our priorities: • Generate higher-dose safety and PK data • Enable a practical subcutaneous dosing approach • Finalize a Phase 2b study with regulatory alignment The goal is to expand what GLP-1s can achieve for patients who need more. Learn more: ir.skyebioscience.com #Biotech #Obesity #ClinicalDevelopment

Skye Bioscience will be presenting at the upcoming GLP-1-Based Therapeutics Summit, a leading forum focused on advancing next-generation therapies in obesity and metabolic disease. We look forward to engaging with the scientific and clinical community as we continue to advance our development programs and explore new approaches to improving metabolic health. Learn more: ir.skyebioscience.com/news-releases/… #Biotech #Obesity #ClinicalDevelopment

We are taking the next step to better understand nimacimab’s full potential. Skye has initiated an expansion of the CBeyond study to evaluate higher doses, building on earlier findings in combination with semaglutide. The goal is to better define the dose-efficacy relationship, confirm safety at higher exposure levels, and inform Phase 2b dose selection. Learn more: ir.skyebioscience.com #Biotech #Obesity #ClinicalDevelopment

Skye continues to build on its focused approach to optimizing dose and exposure of nimacimab. We recently treated the first patient in our higher-dose CBeyond Expansion Study, designed to evaluate the relationship between exposure and safety and inform Phase 2b dose selection. Read the release: ir.skyebioscience.com/news-releases/… #Biotech #Obesity #ClinicalDevelopment

Skye is advancing nimacimab with a clear focus: Optimizing dose and exposure to unlock its full potential. In our CBeyond study, nimacimab demonstrated results in combination with semaglutide. Higher exposure may be needed to engage peripheral CB1 targets. Learn more: ir.skyebioscience.com #Biotech #Obesity #ClinicalDevelopment

Skye continues to advance nimacimab as a potential differentiated therapy for obesity. Progress includes initiating the CBeyond Expansion Study and implement FDA feedback to guide Phase 2b planning. Read more at: ir.skyebioscience.com/news-releases #Biotech #Obesity #ClinicalDevelopment

Today, Skye reported its financial results for the fourth quarter and full year ended December 31, 2025 while also sharing a business update highlighting recent achievements and important milestones ahead. Read the release: ir.skyebioscience.com/news-releases/… #Biotech #Obesity #ClinicalDevelopment

Reminder: Join us today at 4:30 p.m. ET / 1:30 p.m. PT for Skye Bioscience’s webcast to discuss our fourth quarter and full year 2025 financial results and business update. The webcast will be available through our Investor Relations website: ir.skyebioscience.com/company-inform… #Biotech #Obesity #ClinicalDevelopment

Join us on March 10, 2026, as Skye Bioscience reports its 2025 fourth quarter and full-year financial results and provides a corporate update. Read the press release here: ir.skyebioscience.com/news-releases/… #biotech #Obesity #ClinicalDevelopment

Skye reports positive interim CBeyond™ Phase 2a extension results, with 22.3% average total weight loss at 52 weeks for nimacimab in combination with semaglutide. ir.skyebioscience.com/news-releases/… #Biotech #Obesity #ClinicalDevelopment

Skye presented new data at the Keystone Symposium on Obesity, highlighting key attributes of nimacimab, our peripherally restricted CB1 inhibitor antibody. View the poster to learn how nimacimab’s biodistribution supports metabolic activity while limiting central exposure: skyebioscience.com/keystone-2026-…

$SKYE Bioscience will be presenting a poster at the Keystone Obesity Conference. The presentation highlights ongoing scientific work supporting our focus in metabolic disease. Read the press release here: ir.skyebioscience.com/news-releases/…

As we look ahead, $SKYE continues to emphasize disciplined, focused execution across our clinical and development programs. Building on the Phase 2a CBeyond data generated in 2025, this year represents an important opportunity to advance our pipeline. Our priorities include delivering additional clinical readouts, evaluating higher doses of nimacimab, and preparing for a Phase 2b study assessing nimacimab in combination with an incretin therapy, while remaining focused on driving meaningful progress for patients and stakeholders. Read the full release: ir.skyebioscience.com/news-releases/…

$SKYE has partnered with Halozyme Therapeutics to co-formulate nimacimab with its proprietary ENHANZE® technology, which enables higher-volume subcutaneous administration by temporarily modifying the extracellular matrix in the skin. This approach is designed to support faster injections, improved absorption, reduced injection-site discomfort, and enhanced bioavailability. We believe that co-formulating nimacimab with ENHANZE® will allow us to deliver the doses and volumes needed to achieve meaningful weight loss outcomes, while maintaining a subcutaneous injection experience comparable to currently available GLP-1 therapies. Watch our insight video here: skyebioscience.com/working-with-h…

Advancing nimacimab in obesity requires both clinical rigor and delivery flexibility. Our recently announced collaboration with Halozyme Therapeutics enables the evaluation of higher subcutaneous doses, supporting more robust dose optimization. This approach also creates the opportunity to explore combination strategies with GLP-1 receptor agonists, an increasingly important area of differentiation in today’s obesity landscape. As Skye prepares to initiate its Phase 2b trial, this strategy strengthens our development plan and positions nimacimab for a more comprehensive clinical assessment. ir.skyebioscience.com/news-releases/…

Skye & Halozyme @halozymeinc today announced a global collaboration and license agreement to evaluate nimacimab co-formulated with ENHANZE® for the treatment of obesity. The collaboration supports Skye’s ability to test higher-dose subcutaneous delivery of nimacimab, including evaluation in combination with GLP-1 receptor agonists, using Halozyme’s proven drug delivery technology. A Phase 2b obesity trial is planned for mid-2026, marking an important step forward in advancing innovative treatment options in a growing therapeutic area. ir.skyebioscience.com/news-releases/…

Happy New Years from the Skye team! We are focused on 2026 being a pivotal year for the development of nimacimab. 2025 was a tough year and also clarified nimacimab’s path: safe, peripheral MOA through 4 distinct pillars, additive to incretin therapies. ~13% placebo-adjusted weight loss in combo vs ~10% sema alone. Watch: skyebioscience.com/ceo-2025-year-…. #Nimacimab $SKYE Follow for lots more updates coming up.

Happy holidays to everyone including $SKYE shareholders, patients, and team.🎄 Our 2025 Year-in-Review + 2026 plan update by our CEO @PunitDhillon is live on the Spotlight page. TL;DR: nimacimab added ~3% extra weight loss on top of semaglutide at 26 weeks, with no added GI burden and a clean neuropsychiatric profile. Next: higher exposure dosing + 52-week safety, efficacy & durability (Q1’26). // skyebioscience.com/ceo-2025-year-…